POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research[1][2]
A derivative of compstatin, a potent C3 inhibitor, POT-4 is a cyclic peptide that exhibits binding activity to C3, preventing cleavage to its active fragments C3a and C3b[2].
[1]. S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.
[2]. Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40(1):18-26.